How to Navigate Ecosystem Connect NEW Distinguished Investigators 
Global Conferences RLT Education RLT Components Sponsors Trial Stats
Global Conferences RLT Education RLT Components Sponsors Trial Stats 
How to NavigateNEW Ecosystem Connect Distinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats Dictionary About Us Our Values
Contact XCancer
Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comTargeted Radionuclide Therapy for Metastatic Melanoma [131I] ICF01012: Phase I Study
Description:
This study is a phase I clinical trial aimed to determine the recommended dose of [131I]ICF01012 to administer for the treatment of patients with pigmented metastatic melanoma (binding [131I]ICF01012 ). The [131I]ICF01012 is a targeted radionuclide therapy with a high affinity for melanin.
Sponsor:
Centre Jean Perrin
Phase:
Early Phase 1
Contacts:
Florent CACHIN, Pr (Principal Investigator)florent.cachin@clermont.unicancer.fr
33473278089
Government Study Link:
NCT03784625 - Click here to see study onClinicalTrials.gov
Share your feedback
Help us improve your experience